drugset / Trial / NCT00744016

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

NCT00744016

Phase 3 Completed 305 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.

Timeline

Start
2004-12
Primary completion
2007-05
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mesalamine Small molecule 1.5 g Oral

Indications